SAGE Therapeutics (SAGE) Misses Q4 EPS by 10c

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($2.47), $0.10 worse than the analyst estimate of ($2.37). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $1.95 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• MIND Technology (MIND) Misses Q1 EPS by 5c